Qian Gao1, Lirong Chen1, Chenshuang Jia1, Yue Yuan1, Xinyao Li1, Zheng Lu1, Yang Feng1, Ruixia Zhao1, Xuewei Zhao1, Yiwen Wang1, Sinan Cheng1, Caixia Zhang1, Jie Xu1, Zhan Shu1, Wei Duan2, Guochao Nie3, Li Xiao4, Yingchun Hou5. 1. College of Life Sciences, Shaanxi Normal University, Xi'an, 710119, Shaanxi, China. 2. School of Medicine, Deakin University, Waurn Ponds, VIC, 3216, Australia. 3. Guangxi Key Laboratory of Agricultural Resource Chemistry and Biotechnology, Yulin Normal University, Yulin, 537000, Guangxi, China. bccu518@163.com. 4. College of Life Sciences, Shaanxi Normal University, Xi'an, 710119, Shaanxi, China. xiaoli@snnu.edu.cn. 5. College of Life Sciences, Shaanxi Normal University, Xi'an, 710119, Shaanxi, China. ychhou@snnu.edu.cn.
Abstract
OBJECTIVES: Ovarian cancer is one of the most fatal gynecological malignancies. It is emergently needed to select a novel molecular fragment as a targeting element for the future development of molecular imaging diagnosis and targeting chemotherapy to ovarian cancer. RESULTS: After five rounds of biopanning, a total of 44 positive phage clones were selected from final phage displayed peptide library. Nine consensus sequences were found based on the assay of sequencing results, then one clone of each consensus group was characterized and identified further by immunofluorescence assay. The result showed the phage clone R20 presents best targeting capacity. Then we synthesized peptide (OSP2) clone R20 displayed, it was characterized with high specificity and sensitivity binding to human ovarian cancer by a tissue chip assay. The target of OSP2 was predicted and docked as human carbonic anhydrase XII (CA12), an important protein usually deregulated in cancer. CONCLUSIONS: Taken together, OSP2 and its target indicate a novel investigation way in future to develop novel agent or drug delivery formulation for molecular imaging diagnosis and targeting chemotherapy of ovarian cancer.
OBJECTIVES: Ovarian cancer is one of the most fatal gynecological malignancies. It is emergently needed to select a novel molecular fragment as a targeting element for the future development of molecular imaging diagnosis and targeting chemotherapy to ovarian cancer. RESULTS: After five rounds of biopanning, a total of 44 positive phage clones were selected from final phage displayed peptide library. Nine consensus sequences were found based on the assay of sequencing results, then one clone of each consensus group was characterized and identified further by immunofluorescence assay. The result showed the phage clone R20 presents best targeting capacity. Then we synthesized peptide (OSP2) clone R20 displayed, it was characterized with high specificity and sensitivity binding to human ovarian cancer by a tissue chip assay. The target of OSP2 was predicted and docked as human carbonic anhydrase XII (CA12), an important protein usually deregulated in cancer. CONCLUSIONS: Taken together, OSP2 and its target indicate a novel investigation way in future to develop novel agent or drug delivery formulation for molecular imaging diagnosis and targeting chemotherapy of ovarian cancer.
Authors: Christopher M Franke; Vivian W Gu; Benjamin G Grimm; Victoria C Cassady; Jeffrey R White; Ronald J Weigel; Mikhail V Kulak Journal: Oncogene Date: 2019-10-21 Impact factor: 9.867
Authors: Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman Journal: Lancet Date: 2014-11-26 Impact factor: 79.321
Authors: Ashley L Hilchie; Carolyn D Doucette; Devanand M Pinto; Aleksander Patrzykat; Susan Douglas; David W Hoskin Journal: Breast Cancer Res Date: 2011-10-24 Impact factor: 6.466